Mr. Rea co-presented with Dr. Caballido, Novartis Institute for Biomedical Research, on Orally Administered Polymetric Bile Acid Nanoparticles to Restore Glucose Control and Induce Immune Tolerance in Early and Advanced Diabetes.
About Toralgen, Inc.
Toralgen, Inc. is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Its poly-bile nanoparticle platform eliminates many of the inherent challenges of biologics and has the potential to improve outcomes through optimized drug delivery. Toralgen is currently studying treatments for diabetes and autoimmune disorders. For information or to inquire about possible collaborations, visit our website.
Contact: Dave Moore, Toralgen, firstname.lastname@example.org